Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-09-22 am EDT
3403.00 JPY   -1.22%
09/09Japan's Nikkei ends week on a high in hawkish climate
RE
09/08Japanese stocks gain as investors digest cenbank decisions
RE
09/08CHUGAI PHARMACEUTICAL : Summary
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
09/15/2022 09/16/2022 09/20/2022 09/21/2022 09/22/2022 Date
3565(c) 3534(c) 3497(c) 3445(c) 3403(c) Last
1 433 100 2 201 400 1 688 800 1 732 400 1 773 200 Volume
+0.08% -0.87% -1.05% -1.49% -1.22% Change
More quotes
Estimated financial data (e)
Sales 2022 1 209 B 8 441 M 8 441 M
Net income 2022 360 B 2 513 M 2 513 M
Net cash position 2022 529 B 3 691 M 3 691 M
P/E ratio 2022 15,7x
Yield 2022 2,33%
Sales 2023 1 043 B 7 286 M 7 286 M
Net income 2023 319 B 2 229 M 2 229 M
Net cash position 2023 760 B 5 305 M 5 305 M
P/E ratio 2023 17,5x
Yield 2023 2,48%
Capitalization 5 598 B 39 089 M 39 089 M
EV / Sales 2022 4,19x
EV / Sales 2023 4,64x
Nbr of Employees 7 664
Free-Float 38,0%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%). 
Read more
Sector
Pharmaceuticals
Calendar
10/24 | 04:00amEarnings Release
More about the company
Ratings of Chugai Pharmaceutical Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD
09/09Japan's Nikkei ends week on a high in hawkish climate
RE
09/08Japanese stocks gain as investors digest cenbank decisions
RE
09/08CHUGAI PHARMACEUTICAL : Summary
PU
08/24Roche's Japanese Unit Obtains Approval For Anticancer Medication
MT
08/24CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for POLIVY for Additional Indication o..
PU
08/22CHUGAI PHARMACEUTICAL : and Noile-Immune Biotech Enter into a License Agreement for Noile-..
PU
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl..
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/10CHUGAI PHARMACEUTICAL : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C..
PU
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
08/08Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu..
AQ
08/08CHUGAI PHARMACEUTICAL : Notice of the Settlement of Patent Infringement Litigation in the ..
PU
08/08Roche's Chugai Unit Launches Skin Disease Drug in Japan
MT
08/07CHUGAI PHARMACEUTICAL : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc..
PU
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD
08/24L'unité japonaise de Roche obtient l'approbation d'un médicament anticancéreux
08/10Le médicament de Roche contre les maladies sanguines rares obtient une étiquette de rev..
08/10ROCHE : la filiale Chugai cible une homologation en Chine pour le Crovalimab
08/10Roche-Tochter Chugai peilt chinesische Zulassung für Kandidat Crovalimab an
08/08L'unité Chugai de Roche lance un médicament contre les maladies de la peau au Japon
More news
ETFs positioned on CHUGAI PHARMACEUTICAL CO., LTDETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Xtrackers Nikkei 225 1C - JPY1.58%-0.29%-Japan
Xtrackers Nikkei 225 1D - JPY1.39%1.12%Japan
Xtrackers Nikkei 225 2D - EUR Hedged1.39%-3.05%-Japan
Nikko Listed Index Fund Nikkei 225 (Mini) - JPY1.38%-2.30%-Japan
IShares Nikkei 225 - JPY1.38%-3.19%Japan
More ETFs positioned on CHUGAI PHARMACEUTICAL CO., LTD
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 403,00 JPY
Average target price 4 470,00 JPY
Spread / Average Target 31,4%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-8.89%39 089
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392